Now Reading
FDA authorizes new monoclonal antibody treatment
Subscribe
Sign In

FDA authorizes new monoclonal antibody treatment

FDA authorizes a new treatment for Covid. The drug is expected to fight the Omicron.

Where: United States

The Facts

The US Food and Drug Administration(FDA) has issued an emergency use authorization for a monoclonal antibody treatment that is effective against the Omicron variant of the Covid-19 virus.

The FDA news release states, “Bebtelovimab works by binding to the spike protein of the virus that causes COVID-19.”

An Eli Lilly news release states, “Pseudovirus and authentic virus testing demonstrate that bebtelovimab retains full neutralizing activity against Omicron – currently the predominant variant in the US.”

Lilly has signed an agreement with the US government to supply approximately 600,000 doses of bebtelovimab.

Treatment with the new drug has not been studied in patients with Covid-19 who are hospitalized.

Primary Sources

Direct, authoritative source material on this story.

Reference Articles

Articles Citable has ingested related to this story.

Reference Articles

Articles Citable has ingested related to this story.

Media Coverage

Why did we include this story

Most covered story by the media today

of articles referenced this story

Coverage by Media Outlet

Media outlets covering this story along with their positive or negative sentiment toward this story.

© 2021 Citable. All Rights Reserved.